Leveraging CRISPR Technologies for Wider Organ Delivery

• Highlighting how smaller CRISPR enzymes open access to tissues that other delivery systems cannot reach
• Exploring the potential for enzymes to be packaged into more flexible delivery vehicles
• Investigating how enzyme size influences the ability to target previously inaccessible disease sites

Speakers:

Devyn Smith

Chief Executive Officer

Arbor Biotechnologies, Inc.